MedTrace Logo

Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)

NCT03613636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 490

Last updated 2024-02-22

No results posted yet for this study

Summary

To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and serology, in a cohort of children with community-acquired pneumonia (CAP) and controls.

Conditions

  • Childhood Pneumonia
  • Mycoplasma Pneumonia
  • Antibody-secreting Cells
  • Enzyme-linked Immunospot (ELISpot)
  • Diagnosis

Interventions

DIAGNOSTIC_TEST

Enzyme-linked immunospot (ELISpot) assay [Blood]

The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].

Sponsors & Collaborators

  • University Children's Hospital, Zurich

    lead OTHER

Principal Investigators

  • Patrick M. Meyer Sauteur, MD · University Children's Hospital, Zurich

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2020-10-31
Completion
2020-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613636 on ClinicalTrials.gov